Clinical Trials on Cancers Expressing HER-2 and/or CEA in United Kingdom

Total 1284 results

GTx

Completed

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

ER+ and AR+ Breast Cancer

United States
University of Michigan

Terminated

Amlexanox for Type 2 Diabetes and Obesity

Obesity | Diabetes Mellitus Type 2 | Non Alcoholic Fatty Liver Disease

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
PapiVax Biotech, Inc.

Recruiting

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

HPV 16+ Recurrent or Metastatic Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Breast MRI Spectroscopy

Suspicion of, or Known Breast Cancer

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Salivary Gland Cancer | HER2 Gene Mutation

United States
Jonsson Comprehensive Cancer Center
Novartis; Seagen Inc.

Recruiting

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
Weill Medical College of Cornell University

Recruiting

Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment

Gynecologic Cancer | Hereditary Cancer Syndrome

United States
Forma Therapeutics, Inc.

Recruiting

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

United States, France, Canada, Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
University of California, San Francisco
Puma Biotechnology, Inc.

Completed

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

HER2-positive Breast Cancer | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Antonio Giordano, MD
Cardiff Oncology

Recruiting

Onvansertib + Paclitaxel In TNBC

Breast Cancer | Metastatic Breast Cancer | Inflammatory Breast Cancer | Invasive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Hormone Receptor Negative Breast Carcinoma | Hormone Receptor/Growth Factor...

United States
Thomas Jefferson University
National Cancer Institute (NCI); University of California, San Diego; Lantheus...

Completed

Quantitative Subharmonic Breast Imaging

Breast Cancer

United States
Charles Drew University of Medicine and Science

Recruiting

Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes

Colorectal Cancer | Type 2 Diabetes

United States
Myriad Genetic Laboratories, Inc.
Myriad Genetics, Inc.

Completed

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

Hereditary Cancer

United States
Ionis Pharmaceuticals, Inc.

Recruiting

Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome

United States
Puma Biotechnology, Inc.

Completed

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Early Stage HER2+ Breast Cancer

Spain, United States, France, Australia, Germany, Austria, Canada
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Metastatic or Locally-advanced Unresectable Breast Cancer

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Smart Medical Systems Ltd.

Not yet recruiting

A Prospective Randomized Study Comparing the Adenoma Detection Yield of SC, AI and Combined AI and G-EYE®

Adenoma | Colorectal (Colon or Rectal) Cancer

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Unknown

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Stage III Breast Cancer

United States
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
National Cancer Institute (NCI)

Active, not recruiting

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
Celgene

Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...

United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
Ann & Robert H Lurie Children's Hospital of Chicago
Mallinckrodt

Completed

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Leukemia | Cancer

United States
Novo Nordisk A/S

Completed

Diabetes Attitudes Wishes and Needs (DAWN2)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare Professionals

Spain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

HER2-positive Breast Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis

United States
City of Hope Medical Center
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Breast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
Jo Chien
Merck Sharp & Dohme LLC

Completed

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Triple Negative Breast Cancer | Advanced or Metastatic Breast Cancer

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Breast Cancer | Invasive Carcinoma of the Breast | Node Negative Breast Cancer | Micrometastasis Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer

Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma | Estrogen Receptor-Positive Breast Carcinoma

United States
Jonsson Comprehensive Cancer Center
Bayer; Translational Research in Oncology-U.S. Inc. (TRIO-US)

Terminated

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Stage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative and other conditions

United States
Novartis Pharmaceuticals

Recruiting

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers

Japan, Italy, Spain, Singapore, Belgium, Germany, Korea, Republic of, Taiwan, France, Israel, Norway, United States
National Cancer Institute (NCI)

Terminated

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Melanoma | Sarcoma | Thoracic Sarcomas | Thorasic Cancers | Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Eli Lilly and Company

Recruiting

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Type 2 Diabetes | CKD | Overweight or Obesity

Italy, United States, United Kingdom, Canada, Spain
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
University of Pennsylvania
Fox Chase Cancer Center; Columbia University; Thomas Jefferson University

Enrolling by invitation

Penn Medicine Biobank Return of Results Program (ROR)

Cardiovascular Diseases | Cancer | Genetic Disease

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Hormone Receptor-Negative Breast Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Ductal Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Cancer

United States
Vanderbilt University Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Family History and Cancer Risk Study (FOREST)

Cancer-related Problem/Condition | Family Characteristics

United States
Margarita Louise Zuley
National Cancer Institute (NCI)

Recruiting

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Breast Cancer

United States
ML Bio Solutions, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) (Fortify)

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

United States, Netherlands, United Kingdom, Denmark, Australia, Italy, Norway
Dana-Farber Cancer Institute

Active, not recruiting

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Recurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States

Clinical Trials on Cancers Expressing HER-2 and/or CEA in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations